Valuing A Vaccine

So far, September is an "upside down" month. Previously bulletproof mega-cap tech shares plunged into a correction, proving that gods do, in fact, bleed. That, in turn, has translated directly into outperformance for value, small-caps, the equal-weighted S&P (versus its cap-weighted counterpart), and the S&P (versus the Nasdaq 100). Read more: September Tech Correction Turns World Upside Down Some of this may be mechanical. What “optically looks like a ‘Value over Growth’ trade

Join institutional investors, analysts and strategists from the world's largest banks: Subscribe today for as little as $7/month

View subscription options

Or try one month for FREE with a trial plan

Already have an account? log in

2 thoughts on “Valuing A Vaccine”

I don’t grok any of the optimism about a vaccine and a rotation into value. I take it as more Wall Street, sell-side smoke in orifice gibberish to give a reason to keep “investors” all lathered up.

Just Googling around now, if a handful of people want to take the Russian vaccine, there might be some available for them if you are a friend. Otherwise, there is no timeline for when a vaccine will be available for healthcare professionals. Second quarter 2021 seems to be where some expert dart throwers are hitting. No one knows what the delivery method, the manufacturing process, distribution and storage, whether two doses will be required, or even the effectiveness, of any eventual vaccine will be.

About there being a vaccine ready for distribution by November 2nd, maybe it’s the Russian vaccine Trump is talking about.